FDA Approvals, News & Updates
In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn), a novel type of immunotherapy, for the treatment of adults with advanced or spreading uveal melanoma, a rare and aggressive type of melanoma that affects the eye. Kimmtrak is the first drug approved for this type of melanoma. Read More ›